Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B

Journal of Medical Virology

Volumn 83, Issue 7, 2011, Pages 1178-1186

  Lee, Myoung Hee ^a   Lee, Da Mi ^a   Kim, Soon Sun ^a   Cheong, Jae Youn ^a   Cho, Sung Won ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

Chronic hepatitis B; Entecavir; Hepatitis B surface antigen; Treatment response

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; CREATININE; ENTECAVIR; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; TRIACYLGLYCEROL; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG RESPONSE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREDICTION; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; SEROCONVERSION; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; ASPARTATE AMINOTRANSFERASE, CYTOPLASMIC; DNA, VIRAL; FEMALE; GUANINE; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME; VIRAL LOAD;

HEPATITIS B VIRUS;

EID: 79955898168     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.22089     Document Type: Article

References (21)

1. Andersson KL, Chung RT. 2009. Monitoring during and after antiviral therapy for hepatitis B. Hepatology 49:S166-S173.
2. Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Luo K, Wang Y, Hadziyannis S, Wolf E, McCloud P, Batrla R, Marcellin P. 2009. Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 49:1141-1150.
3. Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, So TM, Feinman SV, Mach T, Akarca US, Schutten M, Tielemans W, van Vuuren AJ, Hansen BE, Janssen HL. 2008. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 135:459-467.
4. Cai W, Xie Q, An B, Wang H, Zhou X, Zhao G, Guo Q, Gu R, Bao S. 2010. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. J Clin Virol 48:22-26.
5. Chan HL, Wong VW, Tse AM, Tse CH, Chim AM, Chan HY, Wong GL, Sung JJ. 2007. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 5:1462-1468.
6. Chan HL, Wong VW, Wong GL, Chim AM, Chan HY, Sung JJ. 2008. Early hepatitis B virus DNA suppression can predict virologic response to peginterferon and lamivudine treatment. Clin Gastroenterol Hepatol 6:1022-1026.
7. Cooksley H, Chokshi S, Wedemeyer H, Andereone P, Gilson R, Warnes T, Paganin S, Zoulim F, Jain A, Jame C, Gibbs C, Fry J, Brosgart C, Naoumov N. 2002. Hepatitis B virus-specific T-cell reactivity during adefovir dipovoxil (ADV) treatment: A multicenter, controlled study. J Hepatol 36:7.
8. Fan YF, Lu CC, Chen WC, Yao WJ, Wang HC, Chang TT, Lei HY, Shiau AL, Su IJ. 2001. Prevalence and significance of hepatitis B virus (HBV) pre-S mutants in serum and liver at different replicative stage of chronic HBV infection. Hepatology 33:277-286.
9. Gauthier J, Bourne EJ, Lutz MW, Crowther LM, Dienstag JL, Brown NA, Condreay LD. 1999. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J Infect Dis 180:1757-1762.
10. Jung YK, Kim JH, Lee YS, Lee HJ, Yoon E, Jung ES, Hong SK, Joo MK, Yeon JE, Park JJ, Kim JS, Bak YT, Byun KS. 2010. Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naive, hepatitis B e antigen-positive patients receiving entecavir. J Clin Gastroenterol 44:653-657.
11. Lau GK, Marcellin P, Brunetto M, Piratvisuth T, Kapprell HP, Button P, Batrla R. 2008. On-treatment HBsAg decline during peginterferon alfa-2a (40KD) +/- lamivudine in patients with HBeAg-positive CHB as a potential predictor of durable off-treatment response (abstract no. 910). Hepatology 48:714A.
12. Lee JM, Ahn SH, Chang HY, Shin JE, Kim DY, Sim MK, Hong SP, Chung HJ, Kim SO, Han KH, Chon CY, Moon YM. 2004. Reappraisal of HBV genotypes and clinical significance in Koreans using MALDI-TOF mass spectrometry. Korean J Hepatol 10:260-270.
13. Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. 2003. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: Analysis and review of the literature. Hepatology 37:1309-1319.
14. Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, Dauvergne A, Asselah T, Boyer N, Bedossa P, Valla D, Vidaud M, Nicolas-Chanoine MH, Marcellin P. 2009. Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 49:1151-1157.
15. Ozaras R, Tabak F, Tahan V, Ozturk R, Akin H, Mert A, Senturk H. 2008. Correlation of quantitative assay of HBsAg and HBV-DNA levels during chronic HBV treatment. Dig Dis Sci 53:2995-2998.
16. Sung JJ, Wong ML, Bowden S, Liew CT, Hui AY, Wong VW, Leung NW, Locarnini S, Chan HL. 2005. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 128:1890-1897.
17. Tangkijvanich P, Komolmit P, Mahachai V, Sa-nguanmoo P, Theamboonlers A, Poovorawan Y. 2009. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B. J Clin Virol 46:117-123.
18. Thompson A, Nguyen T, Iser D, Ayres A, Jackson K, Littlejohn M, Slavin J, Bowden S, Gane E, Abbott W, Lau G, Lewin S, Visvanathan K, Desmond P, Locarnin S. 2010. Serum hepatitis B surface antigen and hepatitis B e antigen titers: Disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 51:1933-1944.
19. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, Trepo C, Marcellin P, Goodman Z, Delaney WE IV, Xiong S, Brosgart CL, Chen SS, Gibbs CS, Zoulim F. 2004. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126:1750-1758.
20. Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, Longerich T, Schirmacher P, Metzler F, Zankel M, Fischer C, Currie G, Brosgart C, Petersen J. 2006. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 44:675-684.
21. Yuen MF, Fong DY, Wong DK, Yuen JC, Fung J, Lai CL. 2007. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology 46:1695-1703.